Urge Urinary Incontinence

3
Pipeline Programs
1
Companies
1
Clinical Trials
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
2
Early DiscoveryClinical DevelopmentMarket

On Market (2)

Approved therapies currently available

U
OXYBUTYNINApproved
oxybutynin
Unknown Company
transdermal2014
U
OXYBUTYNIN CHLORIDEApproved
oxybutynin
Unknown Company
oral2017

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Antares Therapeutics
1 program
1
OxybutyninPhase 31 trial
Active Trials
NCT00909181CompletedEst. Nov 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Antares TherapeuticsOxybutynin

Clinical Trials (1)

NCT00909181Antares TherapeuticsOxybutynin

Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence

Start: Mar 2009Est. completion: Nov 2010
Phase 3Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space